Trial Profile

TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eftilagimod alpha (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Paclitaxel
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms TACTI-004
Sponsors Immutep Limited

01 Apr 2025 Status changed from not yet recruiting to recruiting.
25 Mar 2025 According to an Immutep media release, company announced that first patient has been successfully dosed in the pivotal TACTI-004 Phase III trial.
20 Mar 2025 According to an Immutep media release, a trial-in-progress poster will be presented at the European Lung Cancer Congress (ELCC) 2025, taking place in Paris, France, from 26-29 March 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com